Generate Biomedicines
GENB
9.54
-0.83
-8.00%
Generate Biomedicines
US · GENB
#2875 by market cap
Listed 2026
9.54
-0.83
-8.00%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:32
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -3.79, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 2 years
Latest year +55.89% YoY
Margins
- Operating margin
- -737.04%
- Net margin
- -782.38%
Key ratios & quality
- Altman Z-Scorei
- -3.79
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | 20.46M | 31.89M |
| Gross profit | -- | -- |
| Selling & admin expenses | 42.09M | 42.26M |
| Research & development | 175.31M | 224.70M |
| Operating profit | -196.94M | -235.07M |
| Pretax profit | -181.17M | -222.80M |
| Tax | 212.00K | 163.00K |
| Net profit | -181.38M | -222.97M |
| Basic EPS | -2 | -2 |
| Diluted EPS | -2.09 | -2.18 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Revenue | 10.13M | 9.63M | 3.31M | 7.22M | 6.31M | 4.22M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 10.55M | 10.30M | 11.27M | 13.52M | 13.60M | 13.47M |
| Research & development | 59.74M | 62.15M | 55.99M | 57.81M | 64.33M | 82.25M |
| Operating profit | -60.15M | -62.81M | -63.95M | -64.11M | -71.61M | -91.51M |
| Pretax profit | -56.70M | -60.00M | -61.85M | -61.69M | -67.20M | -87.61M |
| Tax | 44.00K | 34.00K | 29.00K | 28.00K | 53.00K | 49.00K |
| Net profit | -56.74M | -60.03M | -61.88M | -61.71M | -67.26M | -87.66M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.63 | -0.51 | -0.53 | -1.07 | -0.52 | -0.68 |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 407.49M | 234.37M |
| Cash & ST investments | 393.63M | 221.50M |
| Inventory | -- | -- |
| Total assets | 518.26M | 330.18M |
| Total current liabilities | 86.63M | 82.20M |
| Short-term debt | 16.72M | 15.01M |
| Long-term debt | -- | -- |
| Total liabilities | 953,349,000.00 | 953,379,000.00 |
| Total equity | -435.09M | -623.20M |
| Retained earnings | -473.14M | -676.29M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Total current assets | -- | -- | 234.37M | 535.39M | 470.25M | 414.64M |
| Cash & ST investments | -- | -- | 221.50M | 516.64M | 457.42M | 404.21M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | -- | -- | 330.18M | 625.74M | 561.69M | 515.89M |
| Total current liabilities | -- | -- | 82.20M | 58.39M | 56.64M | 82.72M |
| Short-term debt | -- | -- | 15.01M | 14.26M | 13.62M | 23.33M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | -- | -- | 953,379,000.00 | 110,936,000.00 | 105,645,000.00 | 134,734,000.00 |
| Total equity | -- | -- | -623.20M | 514.80M | 456.05M | 381.16M |
| Retained earnings | -- | -- | -676.29M | -737.74M | -804.99M | -892.65M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -117.75M | -200.62M |
| Depreciation & amortization | 15.35M | 13.18M |
| Free cash flow | -121.20M | -204.13M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | -- |
| Ending cash balance | 181.83M | 126.04M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | -48.75M | -48.43M | -50.26M | -80.39M | -57.94M | -54.86M |
| Depreciation & amortization | 3.32M | 3.31M | 3.13M | 3.27M | 3.22M | 3.69M |
| Free cash flow | -48.91M | -48.66M | -52.64M | -84.17M | -58.88M | -57.01M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | -- | 369.29M | 0 | 0 |
| Ending cash balance | 158.66M | 123.20M | 126.04M | 164.61M | 139.39M | 144.38M |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -- | -- |
| ROA %i | -41.25 | -58.82 |
| ROIC %i | -- | -- |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -875.18 | -695.03 |
| FCF / sales %i | -- | -- |
| Current ratioi | 4.70 | 2.85 |
| Quick ratioi | 4.55 | 2.69 |
| Debt / assetsi | 14.85 | 20.75 |
| LT debt / equityi | -- | -- |
| Interest coveragei | -84.54 | -195.13 |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -51.56 | -58.91 | -76.38 |
| ROA %i | -- | -- | -58.82 | -42.42 | -47.83 | -56.43 |
| ROIC %i | -- | -- | -- | -46.91 | -53.23 | -65.54 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -695.03 | -789.73 | -943.76 | -1,317.60 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | -- | -- | 2.85 | 9.17 | 8.30 | 5.01 |
| Quick ratioi | -- | -- | 2.69 | 8.85 | 8.08 | 4.89 |
| Debt / assetsi | -- | -- | 20.75 | 10.48 | 11.15 | 14.60 |
| LT debt / equityi | -- | -- | -- | 9.97 | 10.75 | 13.65 |
| Interest coveragei | -- | -- | -195.13 | -251.87 | -313.20 | -376.67 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Field of generative biology by using machine learning for drug discovery and development through the100.00%
Quote time 2026-11-20 19:32:29 · For reference only, not investment advice and not tailored to your situation.
Generate Biomedicines discussion 0 comments